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Abstract
Rationale Ketamine is an N-methyl-D-aspartate (NMDA)
receptor antagonist with psychotogenic effects and for which
there are diverse reports of whether pleasant or unpleasant
dreams result during anaesthesia, post-operatively or after
sub-anaesthetic use.
Objective To assess in healthy volunteers the incidence of
unpleasant dreams over the three nights after receiving a
sub-anaesthetic dose of ketamine, in comparison to place-
bo, and with retrospective home nightmare frequency as a
covariate.
Method Thirty healthy volunteers completed questionnaires
about retrospective home dream recall and were then given
either ketamine (n=19, males=9, mean age=23.5 years; mean
ketamine blood plasma=175.29 ng/mL) or placebo (n=11,
males=5, mean age=25.4 years). Dream recall and pleasant-
ness/unpleasantness of dream content were recorded by
questionnaire at home for the three nights after infusion.
Results Ketamine resulted in significantly more mean
dream unpleasantness relative to placebo and caused a
threefold increase in the odds ratio for the incidence of an
unpleasant dream. The number of dreams reported over the
three nights did not differ between the groups. The
incidence of unpleasant dreams after ketamine use was
predicted by retrospectively assessed nightmare frequency
at home.
Conclusions Ketamine causes unpleasant dreams over the
three post-administration nights. This may be evidence of a
residual psychotogenic effect that is not found on standard
self-report symptomatology measures or a result of dis-
turbed sleep electrophysiology.
Keywords Ketamine . Abuse . Sleep . REM sleep . Dream .
Dreaming . Nightmare . Sub-acute . Schizotypy .
Dissociation . Schizophrenia . NMDA
Introduction
Ketamine is a dissociative anaesthetic that blocks the N-
methyl-D-aspartate (NMDA) receptor. It is used for anaes-
thesia or sedation, usually for brief procedures; as an
analgesic and also as an illegal recreational drug. It can
result in a dissociative state, and as a result of the increase in
schizotypy and psychotic symptoms that it and other NMDA
antagonists (e.g. phencyclidine [PCP]) can cause (e.g. Krystal
et al. 2005; Lahti et al. 2001; Pomarol-Clotet et al. 2006;
Radant et al. 1998; Stone and Pilowsky 2006), an NMDA
receptor hypofunction model of schizophrenia has been
proposed (Fletcher and Honey 2006; Olney et al. 1999).
Although these acute effects have been studied exten-
sively, according to Kennedy and McAllister (2000), little
is known of the medium- to long-term sequelae of ketamine
sedation. Recent experimental work indicates that schizo-
typal and dissociative effects are not found 48 h (Newcomer
et al. 1999) or 3 days after ketamine is taken by ketamine-
naïve volunteers (Morgan et al. 2004a) nor in ketamine
users assessed 3 days after use (Curran and Monaghan
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2001). For clinical studies, although some mild emergence
reactions have been found, for example, in children up to
15 days after surgery with ketamine (Erk et al. 2007), Fine
and Finestone (1973) report just two cases of floating
hallucinations and one of being surrounded by faceless
people during the weeks after operations with ketamine,
from 1,400 operations in total.
The aim of the current paper is to investigate possible
residual effects of ketamine over the days after ingestion by
an assessment of the number and emotional tone of dreams
in the home environment, compared to a placebo group.
Dream recall is chosen in this study as an index of any
prolonged effect of ketamine because increased dream
recall has been found to result during ketamine anaesthesia
(e.g. Grace 2003), in a dose-dependent manner (Edwards et
al. 1993), and lasting for at least 24 h post-operation
(Klausen et al. 1983). Also, there are significant associa-
tions between dream recall frequency and dissociation and
schizotypy in the normal population (Watson 2001). The
emotional tone of dreams is used because frequent night-
mares are associated with schizotypy and dissociation
(Blagrove 2007; Hartmann et al. 1981, Kales et al. 1980;
Levin 1998; Levin and Fireman 2002; Watson 2001, 2003).
The mediating factor for these relationships has been
described by Watson (2001) as the ease with which a
person can pass between different (reality-based and
fantasy-based) states of consciousness.
There have been some case reports of hallucinations and
unpleasant dreams in the days after ketamine administration
(e.g. Hersack 1994; Perel and Davidson 1976), but those
reports have emphasised the rarity of these. Table 1 presents a
review of the quantitative literature on the effects of ketamine
on dreaming for periods of 24 h to 3 months after use and
shows that the number of nightmares or unpleasant dreams in
the nights after ketamine is low in most, but not all, studies.
There is a similar range of findings concerning whether
unpleasant dreams or nightmares result during ketamine
anaesthesia with some reports of frequent nightmares (e.g.
Freuchen et al. 1976; Coppel et al. 1973), a ‘possible’
association with nightmares (Pagel and Helfter 2003), all
dreams being unpleasant (Figallo et al. 1977), that there are
more unpleasant than pleasant dreams (e.g. Krissel et al.
1994; Ellingson et al. 1977; Handa et al. 2000), that
‘terrifying dreams are infrequent’ (Khorramzadeh and Lofty
1976; Lofty et al. 1970) or that there are predominantly
pleasant dreams (e.g. Grace 2003; Hejja and Galloon 1975;
Hersack 1994; Sklar et al. 1981; Sechzer 1984; Fine and
Finestone 1973; Downing et al. 1976; White et al. 1980,
1982). There is no systematic difference in ketamine dose
between these acute studies, despite the large differences in
dream characteristics. For example, 2 mg/kg was used by
Freuchen et al. (1976), Handa et al. (2000) and Hejja and
Galloon (1975) with findings of frequent nightmares,
mostly unpleasant dreams and predominantly pleasant
dreams, respectively.
Findings are thus mixed as regards any acute and sub-
acute effects of ketamine on the emotional content of dreams.
However, this may be due to three areas of methodological
differences between or problems with the studies:
1. Obviously, differences in dream pleasantness under
medical conditions might be caused by factors other
than ketamine dose, making it inappropriate to rely on
the comparison of findings from different studies with
their different populations and procedures. For example,
Cunningham and McKinney (1983) state that rapport
with the anaesthetist may reduce any unpleasant vivid
imagery. More appropriate for dose comparisons is that
two studies have assessed different doses of ketamine
within one study. One (Torvaldsson et al. 2005) found
vivid dreams, nightmares and mild hallucinations after
350 mg ketamine but not after 120 mg, whereas the other
(Sechzer 1984) found no ketamine dose differences
between those with pleasant and those with unpleasant
dreams.
2. Most of the above studies did not have a control group.
It may thus be that negative dream emotions in some of
the medical studies may be due to concerns about
having an operation. For example, Kain et al. (1996)
report 54% of children exhibited some negative
behavioural responses 2 weeks after anaesthesia with
O2–N2O and halothane, but without ketamine, and
these responses included nightmares, anxiety and eating
problems. Also, Sechzer (1984) found a higher per-
centage of unpleasant dreams in obstetric patients not
given ketamine (52%) than in those given ketamine
(35%), although the former did have a lower amount of
dream recall (5.6%) than did the ketamine group (35%).
3. None of the above studies on dreams and nightmares after
ketamine controlled for background home level of report-
ing of nightmares, although the association with home
dream recall has been investigated. In Hejja and Galloon
(1975), 45% of patients were home-dreamers (‘defined as
those patients who ordinarily dream at home’), and the
incidence of dreams during ketamine anaesthesia among
them was 75%, whereas only two of the 82 non-home-
dreamers had a dream during the anaesthetic. Also,
White et al. (1982) state that the incidence of emergence
reactions are higher in people who normally dream, as
well as in those with a history of personality problems.
It should also be noted that many of the post-operative
studies reviewed above involved children. As adults tend to
have worse experiences with ketamine than do children
(Green and Johnson 1990; Green and Sherwin 2005; Green
et al. 1990; Sherwin et al. 2000; Sussman 1974), they may
be having frequent nightmares or unpleasant dreams during
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the post-operative nights. Any such worse reactions in
adults would occur despite the fact that idiopathic night-
mares are more frequent in children (Muris et al. 2001) and
adolescents (Nielsen et al. 2000) than in adults.
Aims of this study
Aim 1. To assess whether the incidence of all dreams,
incidence of unpleasant dreams or mean dream
unpleasantness differs between ketamine and
placebo groups in the three nights after ketamine
is given. As surgery itself can result in a rebound
of rapid eye movement (REM) sleep two to four
nights after the operation with heavy density of
eye movements and vivid nightmares (Knill et al.
1990), we studied healthy volunteers so as to
remove this confound and to test the specific
effects of ketamine.
Table 1 Effects of ketamine on dream reports for periods of 24 h to 3 months after use
Authors (date) Dose Age
category
Finding
Dal et al. (2007) 0.5 mg/kg Children Three out of 60 children had bad dreams during the first
post-operative night, which is no higher than controls
Erk et al. (2007) 7 mg/kg Children Nightmares occurred to 7.1% of children over the 24 h
after surgery, but not at all after this
Funk et al. (2000) 6 mg/kg Children Parents were interviewed 1 and 7 days after their children
(age 2–10 years) had surgery. Of the 36 children
receiving ketamine, four had nightmares on the first
night and five had nightmares between the first and
seventh nights. [For the 39 children receiving
midazolam, the numbers with nightmares were two on
the first night and one between the first and seventh nights.]
Hostetler and Davis (2002) 0.5–2.5 mg/kg+midazolam and atropine Children Studied 301 children (6 months–18 years). Night 1: five
bad dreams and three severe awakenings, over first
week: eight bad dreams/nightmares and three children
had unpleasant awakenings, over first month: five
nightmares/bad dreams, two children having unpleasant
awakenings (i.e. 1.7% bad dreams on first night, 2.7% in
first week and 1.7% in first month)
Klausen et al. (1983) 2.2 mg/kg (range 1.7–4.5 mg/kg) Adults Twenty patients interviewed 3 months after low-dose
ketamine infusion, only one of them had had
nightmares, which had lasted 2 weeks from discharge
Krystal et al. (1994) 0.5/0.1 mg/kg Adults No psychological effects, including no nightmares, at
follow-up on the day after being given low- or high-
dose sub-anaesthetic ketamine. On the test day, those
given low doses (0.1 mg/kg) found the experience
pleasant, whereas at 0.5 mg/kg, responses ranged from
enjoyment to fear with this dose being anxiogenic and
causing paranoia in some subjects
Kwok et al. (2004) 0.15 mg/kg Adults No post-operative hallucinations or bad dreams
McGlone et al. (2004) 2–2.5 mg/kg Adults Two percent nightmares or disturbed sleep on the night
after discharge, not persisting longer than this
Meyers and Charles (1978) 3.0 and 3.3 mg/kg Children Present ‘to our knowledge … the first reported cases of
prolonged problems following ketamine administration
in children.’ One 3-year-old with nightmares for 1 year
after 3.0 mg/kg ketamine and one 3-year-old awakening
screaming two to four times per night for a month after
3.3 mg/kg
Valentin and Bech (1996) Cochleography group: 8–10 mg/kg
induction, maintained with 0.5–1 mg/kg
doses. Higher doses with squint group
Children Seventeen percent of patients (median age 2.25 years)
had nightmares later than 3 days after having ketamine
anaesthesia for cochleography. This occurred for 5% of
children having surgery for squints
Wathen et al. (2000) 1 mg/kg Children Over 2 weeks at home, nightmares occurred in 10.3% of
cases and in 9.6% of those also given midazolam. Only
3.4% had pleasant dreams
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Aim 2. To use home nightmare frequency as a covariate in
the comparison of dream unpleasantness between
the ketamine and control groups.
Aim 3. To investigate whether individual differences in
nightmare frequency at home or on-drug schizo-
typy or dissociation are predictive of the presence
of unpleasant dreams after ketamine use. This will
test the statement of Mattila et al. (1979) that
unpleasant or terrifying dreams due to ketamine
cannot be predicted.
Aim 4. To assess any differences between the ketamine
and placebo conditions across the three post-
treatment days in anxiety and depression. This is
because anxiety and depression have small but
significant associations with nightmare frequency
(Blagrove et al. 2004), and hence, may mediate
the effects of ketamine on dream unpleasantness.
Materials and methods
Design
An independent groups design was used in which male and
female participants were randomly allocated to treatment of
an infusion with one of two doses of ketamine or with
placebo. The three groups were balanced for gender with
eight females and eight males in each. Double-blind
procedures were used throughout.
Participants
Participants were recruited through an advertisement and
were paid for their participation. The study was carried out
in accordance with the Declaration of Helsinki and was
approved by the UCL/UCLH ethics committee. All partic-
ipants gave written, witnessed, informed consent on two
occasions: at screening and then at the beginning of the
testing session. Screening of participants followed the same
procedures as used in a previous study (Morgan et al.
2004b). Participants underwent a semi-structured inter-
view to investigate psychiatric history, and drug use was
verified by urinalysis. Inclusion criteria were that partic-
ipants were between 18 and 35 years old and native
English speakers. Exclusion criteria were current, past or
a family history of psychiatric disorders, substance
misuse and general health problems. Forty-eight partic-
ipants completed the ketamine infusion stage of the
study, one participant dropped out of the study during
infusion of high-dose ketamine.
Thirty participants returned their baseline pre-testing
session retrospective dream questionnaires and their post-
testing session dream diaries (low-dose ketamine, n=8; high-
dose ketamine, n=11; placebo, n=11). As there were no
significant differences on any variables between the low- and
high-dose ketamine groups and in order to provide a larger
group for the analysis of predictor variables, the ketamine
groups are combined in most statistical analyses. Demo-
graphic data for the study are thus: ketamine group, n=19,
females=10, males=9, mean age=23.53 (SD=4.51); placebo
group, n=11, females=6, males=5, mean age=25.36 (SD=
4.50).
Procedure
Initial screening session
Participants completed demographic details, Beck Depression
Inventory, Spielberger State Trait Anxiety Inventory Form Y-
2 (Trait Anxiety), Dissociative Experiences Scale and the
Retrospective Dream Questionnaire.
Before drug administration
Testing began at either 9 A.M. or 1 P.M. and the time of
testing was matched across groups. Participants arrived at
the hospital after completing an overnight fast for morning
testing or a minimum of 6 h fasting for afternoon testing.
They were assessed on the pre-drug subjective effects
battery for 20 min, then allowed to rest for 15 min and were
then cannulated. Approximately 5 min after cannulation,
the anaesthetist began the infusion.
Drug administration
A 16-gauge intravenous cannula was inserted in the
non-dominant forearm. Ketamine infusion was via a
Graseby intravenous infusion pump controlled by the
Stanpump programme (Schafer et al. 1990). The
programme uses a bolus–elimination–transfer (BET) infu-
sion scheme which aims to achieve the target plasma
concentration almost instantaneously by taking into account
ketamine pharmacokinetics using a three-compartment model
(Domino et al. 1984). Participants received either ket-
amine (low-dose or high-dose) or placebo (0.9% NaCl
solution). A peripheral venous blood sample was taken
50 min after commencing the infusion. The blood sample
demonstrated that target concentrations (originally 100
and 200 ng/mL) were exceeded. For the participants
included in the present paper, blood plasma concentra-
tions were: low-dose ketamine (n=8), 114.97 ng/mL
(SD=36.55); high-dose ketamine (n=11), 219.17 ng/mL
(SD=35.20). Throughout the 60-min infusion, each
participant’s pulse, blood pressure and electrocardiogram
were monitored.
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After drug administration
On-drug subjective effects questionnaires were completed
40 min after the start of infusion. Participants were then
provided with light refreshments, were assessed 30 min
later and then at hourly intervals by the medical staff as to
their ‘street readiness’ and were discharged approximately
2 h following infusion. Participants were given the
telephone number of a clinical psychologist and an
anaesthetist in case of adverse after effects; none were
reported. Participants took home the three-night dream and
mood questionnaire.
Assessments
Retrospective dream questionnaire
Participants rated their frequency of dream recall in answer
to the question ‘How often do you wake up and remember a
dream’ by indicating one of six response boxes: four to
seven times per week; one to three times per week; one to
three times per month; less than once per month; about
once per year or less and never.
Participants were then given definitions of night terrors
and of nightmares, so that they could distinguish the two
and estimate their frequency of nightmares without
confounding them with night terrors. They were told: ‘A
night terror is a sudden awakening in fear, possibly
accompanied by a scream, but where you do not
remember a dream’. The definition of a nightmare was
given as: ‘A vivid dream that is frightening or disturbing,
the events of which you can remember clearly and in
detail on awakening’. They were asked to estimate their
nightmare frequency using the same six categories as for
the question on dream recall.
Subjective effects questionnaires
Adapted Dissociative States Scale The Adapted Dissocia-
tive States Scale (ADSS) questionnaire consists of the
subjectively rated items of the Clinician Administered
Dissociative States Scale (Bremner et al. 1998).
Schizotypal Symptomatology Questionnaire The 26-item,
self-rated Schizotypal Symptomatology Questionnaire
(SSQ) was employed to assess state schizotypal positive
symptomatology (Curran and Morgan 2000).
Visual analogue scales (VAS) mood assessments were
conducted of contented/discontented, troubled/tranquil,
tense/relaxed, happy/sad and withdrawn/gregarious. Each
VAS was scored 0 (first adjective) to 100 (second
adjective).
Dream and mood questionnaire (completed post-drug
at home for 3 days and nights)
Ratings of anxiety and depression were made in the evening
on two scales, one for the dimension relaxed–anxious and
one for happy–depressed, anchored as very relaxed (1), quite
relaxed (2), neither or mixed (3), quite anxious (4) and very
anxious (5) and as very happy (1), quite happy (2), neither or
mixed (3), quite depressed (4) and very depressed (5),
respectively. Responses halfway between these five points
were allowed (i.e. 1.5, 2.5, 3.5 and 4.5).
After waking, participants rated the presence of individ-
ual emotions in any dreams that had occurred, following the
method of Fosse et al. (2001). The instructions were:
‘For each dream, please indicate whether any of the
following emotions occurred in the dream. If an emotion
occurred, use a number from 1 to 3 to show how intense it
was, where 1 is low, 2 is medium and 3 is high’. The
emotions were listed as: anger; anxiety/fear; sadness; shame;
joy/elation; love/erotic; surprise; other (please specify).
Participants then rated ‘the overall mood of the dream’ on a
pleasantness/unpleasantness scale, anchored as very pleasant
(1), quite pleasant (2), neither or mixed (3), quite unpleasant (4)
and very unpleasant (5), adapted from the dream hedonic tone
scale of Foulkes et al. (1966). Responses halfway between
these five points were allowed (i.e. 1.5, 2.5, 3.5 and 4.5).
After having completed these ratings for any other dream
that was recalled, they then completed the relaxed–anxious
and happy–depressed scales again for how they were
feeling that morning.
Cognitive assessments were also performed for semantic
priming tasks, which are reported elsewhere (Morgan et al.
2006b).
Results
There were no significant differences between the high- and
low-dose ketamine conditions for any variable. For example,
on-drug schizotypy [means (SD): low-dose=9.25 (SD=9.25);
high-dose=12.22 (15.02)] and on-drug dissociation [low-
dose=14.38 (12.07); high-dose=14.22 (14.19)]. The low- and
high-dose groups are thus combined for statistical analyses that
compare the ketamine and placebo conditions. There were no
sex differences on any of the variables, except for baseline
schizotypy [means (SD): males=13.77 (16.41), females=2.25
(3.36), Mann–Whitney U=35.5, z=3.14, p=0.002].
Retrospective dream measures
Table 2 shows the retrospective dream recall frequencies of
the ketamine/placebo groups. The groups did not differ
significantly on dream recall frequency (chi square (4)=
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2.02). From this categorical data, retrospective dream recall
frequency can be calculated as approximately 9.9 dreams
per month for the ketamine group and 12.1 dreams per
month for the placebo group.
Table 3 shows the retrospective nightmare frequencies of
the two drug groups. The groups did not differ significantly on
nightmare frequency (chi square (4)=4.96). From this categor-
ical data, retrospective nightmare frequency can be calculated
as approximately 1.1 nightmares per month for the ketamine
group and 1.6 nightmares per month for the placebo group.
State and trait psychopathology measures
Table 4 shows the descriptive statistics for the data collected
before drug administration and the state schizotypy, dissoci-
ation and VAS mood data before and during drug administra-
tion for the ketamine and placebo groups. The only significant
differences between the two groups were for pre-drug VAS
tense/relaxed (Mann–Whitney U=46.50, z=2.36, p<0.05),
on-drug VAS tense/relaxed (Mann–Whitney U=39.00, z=
2.70, p<0.01), on-drug VAS withdrawn/gregarious (Mann–
Whitney U=40.00, z=2.65, p<0.01), on-drug schizotypy
(Mann–Whitney U=54.00, z=2.03, p<0.05) and on-drug
dissociation (Mann–Whitney U=28.00, z=3.136, p=0.002).
From the results of the contented/discontented; troubled/
tranquil; tense/relaxed, and happy/sad VAS, the experience
was marginally more unpleasant for the ketamine group.
Effects of ketamine on anxiety and depression
over the 3 days after drug use
There were no significant differences in anxiety or
depression between any of the 3 days for either group.
The scores for the 3 days were thus combined to produce a
mean score for anxiety and a mean score for depression at
each of the times of testing: evening and morning. Table 5
shows that there were no significant differences between
the ketamine and placebo groups on these depressed–happy
[F(1, 28)=0.50] or anxious–relaxed [F(1,28)=2.35] scores.
Depression and anxiety were each significantly higher in
the morning than in the evening [depression: F(1,28)=5.93,
p=0.022; anxiety: F(1,28)=10.27, p=0.003]. The differ-
ences between morning and evening did not interact with
drug condition for either anxiety or depression.
Effects of ketamine on dream recall and dream hedonic
tone during the three post-drug administration nights
Shapiro–Wilk tests showed that home nightmare frequency,
home dream frequency and mean hedonic tone were not
normally distributed, and so non-parametric statistics are used.
Kendall’s correlation of concordance is used so as to allow for
partial correlations. Critical values for p of partial correlation
tau-b are taken from Maghsoodloo and Pallos (1981).
The ketamine and placebo groups did not differ on the
number of dreams over the three nights after treatment
[ketamine: n=19, mean (SD)=2.63 (1.89); placebo: n=11,
mean (SD)=2.36 (1.69): Mann–Whitney U=98.00, z=
0.284, n.s.]. Twenty-five participants reported at least one
dream (ketamine low-dose, n=5; ketamine high-dose, n=
11; placebo, n=9); dream content analyses are conducted
on the two groups: ketamine, n=16 and placebo, n=9.
There were no differences in dream unpleasantness between
the three nights for the placebo (Friedman’s test, chi square
(2)=0.29) or ketamine group (chi square (2)=0.54) and for
the low- and high-dose ketamine groups assessed separately
Table 3 Retrospective night-
mare frequencies for the ket-
amine and placebo groups
Groups do not differ signifi-
cantly on nightmare frequency,
chi square (4)=4.96
Retrospective nightmare frequency Total
Four to seven
times per week
One to three
times per week
One to three
times per
month
Less than once
per month
Once a year or
less
Placebo 1 4 2 4 0 11
Ketamine 1 4 8 3 3 19
Total 2 8 10 7 3 30
Table 2 Retrospective dream
recall frequencies for the ket-
amine and placebo groups
Groups do not differ signifi-
cantly on dream recall fre-
quency, chi square (4)=2.02
Retrospective dream recall frequency Total
Four to seven
times per
week
One to three
times per
week
One to three
times
per month
Less than
once
per month
Once a
year
or less
Placebo 3 7 0 1 0 11
Ketamine 4 10 2 2 1 19
Total 7 17 2 3 1 30
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(chi square (2)=3.00 and 0.67, respectively), and so data
for the three nights are combined. Table 6 shows that the
ketamine group scored significantly higher on dream
unpleasantness on the dream hedonic tone scale than did
the placebo group [Mann–Whitney U=37.00, z=2.002, p=
0.045; Kendall’s tau=0.35, p=0.045; for the sexes analysed
separately, females (n=14), tau=0.52, p=0.03, males (n=
11), tau=0.19] and became more significant when home
retrospective nightmare frequencywas partialled out (Kendall’s
partial tau=0.45, p=0.002). The Kendall correlation coeffi-
cient between ketamine blood plasma level and mean dream
unpleasantness was negligible for the low-dose ketamine
group (tau=0.00, n=5) but was significant for the high-dose
group (tau=0.50, p=0.039, n=11).
The amounts of positive and negative emotions in the
dreams were calculated according to the method of Fosse et
al. (2001). Dream emotions were categorised as either
positive (joy/elation; love/erotic; other positive emotions)
or negative (anger; anxiety/fear; sadness; shame; other
negative emotions). The intensities of the positive emotions
and the negative emotions were each summed and then
divided by the total number of dreams. This produced the
total positive emotions and total negative emotions meas-
ures. Following Fosse et al., surprise was not included in
either total positive emotions or total negative emotions and
is calculated as the sum of intensities of surprise divided by
the total number of dreams. The results for total positive
emotions, total negative emotions and surprise are shown in
Table 6.
The ketamine and placebo groups did not differ
significantly on total negative emotions (Mann–Whitney
Table 5 Drug effects on anxiety and depression, assessed in the
evening and in the morning and averaged across the three post-drug
days
Ketamine (n=19) Placebo (n=11)
Mean SD Mean SD
Depression in eveninga 2.25 0.65 2.09 0.79
Depression in morninga 2.54 0.52 2.39 0.71
Anxiety in eveningb 2.22 0.54 1.91 0.80
Anxiety in morningb 2.60 0.61 2.23 0.73
a Depressed–happy scale: very happy=1, very depressed=5
b Anxiety–relaxed scale: very relaxed=1, very anxious=5
Table 4 Pre-drug and on-drug descriptive statistics for trait and state psychopathology and mood measures
Ketamine (n=19) Placebo (n=11)
Mean SD Mean SD
Beck Depression Inventory 4.53 4.94 3.55 5.68
Trait anxiety 18.00 7.91 13.45 13.13
Dissociative experiences 24.21 14.68 23.09 19.23
Contented/discontented pre-druga 25.06 19.42 20.82 18.16
Contented/discontented on-druga 21.67 16.39 13.18 12.54
Troubled/tranquil pre-druga 72.39 17.09 82.18 14.23
Troubled/tranquil on-druga 72.39 18.74 84.55 11.01
Tense/relaxed pre-druga 61.94* 19.91 79.91* 16.68
Tense/relaxed on-druga 63.89** 24.05 84.82** 12.17
Happy/sad pre-druga 20.89 10.13 14.00 10.08
Happy/sad on-druga 23.44 16.72 21.00 28.63
Withdrawn/gregarious pre-druga 66.50 16.18 66.36 17.48
Withdrawn/gregarious on-druga 50.72** 21.90 74.18** 20.97
State schizotypy pre-druga 4.89 4.75 11.55 19.14
State schizotypy on-druga 10.78* 11.99 7.91* 12.76
State dissociation pre-druga 1.00 2.59 1.36 3.64
State dissociation on-drugb 14.29 *** 12.82 1.82*** 2.86
*p<0.05; **p<0.01; ***p=0.002
a Ketamine group n=18 due to missing data
b Ketamine group n=17 due to missing data
Table 6 Effects of ketamine on dream hedonic tone, total positive and
negative emotions and surprise
Data from participants who
reported at least one dream
Ketamine (n=16) Placebo (n=9)
Dream hedonic tonea 3.25* 0.67 2.71* 0.69
Total positive emotions 0.34**, *** 0.56 1.21** 0.88
Total negative emotions 1.35*** 0.98 1.54 2.55
Total surprise 0.42 0.53 1.20 1.12
*p<0.05, differs between groups; **p=0.005, differs between groups;
***p<0.01, differs within subjects
a 1=very pleasant, 5=very unpleasant
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U=55.50, z=0.94) nor on total surprise (Mann–Whitney
U=39.00, z=1.92). However, total positive emotions was
significantly higher for the placebo group than for the
ketamine group (Mann–Whitney U=25.0, z=2.78, p=
0.005). For the placebo group, total positive emotions and
total negative emotions did not differ significantly (Wilcoxon,
z=0.18), whereas the ketamine group had significantly
higher total negative emotions than total positive emotions
(Wilcoxon, z=2.61, p=0.009). Within the low-dose ketamine
group, all correlations between ketamine dose and total
positive emotions, total negative emotions and total surprise
were not significant. Within the high-dose group, there was a
significant correlation only between dose and total negative
emotion (tau=0.67, n=11, p=0.005).
Effects of ketamine on incidence of unpleasant dreams
during the three post-drug administration nights
Incidence of unpleasant dreams was defined as whether
participants had at least one dream over the three nights rated
at least 4 on the pleasantness/unpleasantness scale. Table 7
shows the contingency table for the presence/absence of an
unpleasant dream over the three nights after drug adminis-
tration for the ketamine and placebo groups. Ketamine did
not have a significant effect on incidence of unpleasant
dreams (tau=0.25), but when home nightmare frequency was
partialled out, the effect became significant (Kendall’s partial
tau=0.35, p=0.008). Odds ratio of effect of ketamine on the
presence of an unpleasant dream was 2.96 (95%CI=0.596,
14.729). The effect of ketamine was greater for females (n=
16, tau=0.33) than for males (n=14, tau=0.15).
The Kendall correlation coefficient between ketamine blood
plasma level and unpleasant dream incidence were negligible
for the low-dose ketamine group (tau=−0.09, n=8) but was
larger for the high-dose group (tau=0.44, p=0.10, n=11).
Predictors of dream variables for the ketamine group
Home dream recall predicted post-drug dream recall for the
ketamine group (Kendall’s tau=0.49, p=0.01). The association
was not significant for the placebo group (Kendall’s
tau=0.26). Unpleasant dream incidence was significantly
associated with home nightmare frequency for the ketamine
group [tau=0.58, p=0.008; females (n=10) tau=0.45, males
(n=9) tau=0.75 (p=0.022)]: participants given ketamine who
reported having one nightmare per year or less on the
retrospective questionnaire had no unpleasant dreams over
the three post-ketamine nights.
Table 8 shows that there were non-significant associa-
tions between unpleasant dream incidence and on-drug
schizotypy and dissociation scores and negligible relation-
ships between unpleasant dream incidence and baseline
schizotypy and dissociation. There were no significant
relationships between incidence of unpleasant dreams and
on-drug VAS measures of the unpleasantness/pleasantness
of the experience; the association of incidence of unpleas-
ant dreams with VAS withdrawn/gregarious (tau=−0.41,
p<0.05) was not significant after correction for family-wise
type 1 error due to multiple correlations.
Ketamine-induced deficits in semantic priming for this
study are reported in Morgan et al. (2006b): scores on
semantic priming variables were not predictive of incidence
of unpleasant dreams (all taus<0.20).
Discussion
Administration of a sub-anaesthetic dose of ketamine
resulted in a greater incidence of unpleasant dreams and
more mean unpleasantness of dreams compared to placebo
over the three nights after administration. This effect seems
to be due to the diminishing of positive dream emotions,
rather than an intensification of negative emotions; the
results of the placebo condition accorded with findings in
the literature that positive and negative dream emotions are
balanced across participants (Fosse et al. 2001; Schredl and
Table 8 Kendall’s tau correlations between incidence of unpleasant
dreams after ketamine and pre-drug and on-drug schizotypy and
dissociation measures and on-drug mood measures
Tau
State schizotypy pre-drug −0.08
State schizotypy on-drug 0.33
State dissociation pre-drug 0.01
State dissociation on-druga 0.34
Contented/discontented on-drug 0.03
Troubled/tranquil on-drug −0.10
Tense/relaxed on-drug −0.40
Happy/sad on-drug 0.05
Withdrawn/gregarious on-drug −0.41
Data for ketamine group, n=18 due to missing data from one
participant
a Ketamine group n=17 due to missing data
Table 7 Contingency tables reporting effect of ketamine on incidence
of unpleasant dreams over the three nights after ketamine administration
Ketamine Placebo
For all participants n=19 n=11
At least one unpleasant dream 10 3
No unpleasant dreams 9 8
Kendall’s tau association between drug condition and presence/
absence of at least one unpleasant dream=0.25; Kendall’s partial tau
association between drug condition and presence/absence of at least
one unpleasant dream when home nightmare frequency was partialled
out=0.35, p=0.008
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Doll 1998). The effect of ketamine is not due to state anxiety
or depression over the three post-drug days, as the ketamine
and placebo conditions did not differ on these variables, and is
unlikely to be due to any general unpleasantness of the
ketamine experience, as there was little difference between the
ketamine and placebo conditions on VAS measures of
the unpleasantness of the experience.
These results can be interpreted as evidence for residual
emergence effects of ketamine use with the decrease in
positive dream emotions in the ketamine group possibly
due to the anhedonia that is a component of schizotypy and
dissociation. For example, Krystal et al. (1994) reported
that subjects were emotionally blunted and dulled during
the day of receiving ketamine, and anhedonia with anxiety
and some suspiciousness is described by Duncan et al.
(2001) for normal subjects given sub-anaesthetic ketamine.
Although such residual effects have only been observed
over some hours after ketamine administration, low-level
effects might be present for longer but masked during
wakefulness by the volume of other cognitive activity.
This explanation for the results accords with the proposal
that ketamine may model aspects of psychosis. Although
the literature on the association of schizotypy and night-
mare frequency does not distinguish between positive and
negative schizotypal symptoms, the present study found for
the ketamine group that unpleasant dream incidence had an
association with on-drug social withdrawal of tau=0.41,
which is comparable in size to the association with on-drug
(positive) schizotypy (tau=0.33). Given also that the
ketamine group reported significantly higher on-drug
schizotypy and withdrawal than placebo, the current study
supports previous research showing that acute ketamine
mimics both positive and negative psychosis-like symptoms
(Krystal et al. 2005; Lahti et al. 2001).
One other possible explanation for these effects of
ketamine on dream unpleasantness, however, concerns the
effects of ketamine on sleep. Both racemic and S-ketamine
result in an increase in high-frequency electroencephalo-
gram (EEG; above 20 Hz) during anaesthesia (Maksimow
et al. 2006), and there is electrocerebral and subjective
activation in the wake state (Knott et al. 2006) after sub-
anaesthetic ketamine. Campbell and Feinberg (1999) found
that changes in EEG spectra following the NMDA
antagonist MK-801 were similar to changes caused by
sleep deprivation with large increases in non-rapid eye
movement (NREM) delta and REM 10–20 Hz power. The
enhancing of 10–20 Hz power during REM sleep by
NMDA was also found by Lydic and Baghdoyan (2002).
Ketamine also increases cortical acetylcholine (Kim et al.
1999), upon which REM sleep is dependent (Rye 1997),
and there is a REM rebound following the increase in
NREM delta over the 12 h after ketamine (Feinberg and
March 1995). Such an activating effect on sleep would
cause an intensification of dream imagery (Dement 1960;
Nielsen et al. 2005). However, as the greater unpleasantness
of the dreams of the ketamine group seems to result from a
diminishing of positive emotions, rather than an intensifi-
cation of negative emotions, it is unclear how an intensi-
fication of dream imagery could have resulted in such a
profile of differences in dream emotions between the
ketamine and placebo groups. Also, positive dream emo-
tions have been found to be of equal intensity to negative
emotions in dreams by St-Onge et al. (2005) and slightly
less intense than negative emotions by Schredl and Doll
(1998), and so arguably, negative emotions would not be
preferentially augmented by an intensification of dreaming.
It should also be noted that dream recall over the three
nights after administration was anyway not higher in the
ketamine group. However, neither self-ratings nor objective
measures of sleep length and quality were taken in the
present study, and so it remains possible that, in this study,
the effects on dream unpleasantness were mediated by sleep
variables.
Individual differences in the incidence of unpleasant
dreams after ketamine were significantly associated with
retrospective home nightmare frequency. It is possible that
this is because those high in home nightmare frequency are
high in associated traits (e.g. thin boundariness, absorption,
neuroticism; Blagrove 2007) that might interact with the
state effects of ketamine to produce unpleasant dreams.
Although retrospective measures of nightmare frequency do
provide lower estimates of nightmare frequency than do
prospective diary measures (Blagrove et al. 2004), this
measure may be useful in the medical use of ketamine as an
indicator of increased likelihood of unpleasant dreams. The
co-use of other drugs during anaesthesia [e.g. benzodiazepines
(Grace 2003), clonidine (Handa et al. 2000), diazepam and
midazolam (Hersack 1994)] can reduce the incidence of
unpleasant dreams such that this prediction is in those
circumstances not necessary, but prediction of the incidence
of unpleasant dreams should be considered where ketamine
is the sole agent used, such as in analgesia and minor
surgery.
It is unclear how to interpret the finding that the effect of
ketamine on dream unpleasantness was greater for females
than males, given that this study also found, as did previous
work (Morgan et al. 2006a), that there are no sex
differences in on-drug psychotic symptoms or dissociation
due to ketamine (although the latter authors did find that
there are larger ketamine-induced memory deficits for
males than for females). There have been findings that
females report nightmares more often than do males (e.g.
Levin 1994; Nielsen et al. 2006), but this has sometimes
not been replicated (e.g. Chivers and Blagrove 1999).
Future work should thus address whether this sex difference
is a chance effect, a result of a more general propensity of
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females to have unpleasant dreams or to be willing to report
them (an effect not anyway present in our baseline
retrospective data) or a novel neurochemical finding for
ketamine.
In conclusion, sub-anaesthetic ketamine produces an
increase in dream unpleasantness over the three nights after
drug use, especially for females. This may be mediated by
residual schizotypy and dissociative effects. Retrospective
frequency of nightmares was a significant predictor of
incidence of unpleasant dreams and should be controlled
for in future studies of the effects of ketamine on dreaming.
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